Detection of MRI‐Invisible Disease Using PSMA PET/CT in a Patient Considering Focal Therapy
Patient selection for focal therapy (FT) of prostate cancer requires the assessment of MRI and biopsy results. However, there is currently little guidance for the utility of PSMA PET/CT in FT planning. We describe the case of a man originally considered an ideal candidate for FT based on biopsy and MRI who was found to have a contralateral lesion-harboring cancer detected only on PSMA PET/CT. <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT05852041.
Authors
- Edward M. Schaeffer (ORCID: https://orcid.org/0000-0003-0699-1899)
- Ridwan Alam (ORCID: https://orcid.org/0000-0001-7805-9596)
- Ashley E. Ross (ORCID: https://orcid.org/0000-0001-7044-9688)
- A. Jawahar (ORCID: https://orcid.org/0000-0002-1541-7568)
- Hatice Savas (ORCID: https://orcid.org/0000-0002-9835-9630)
- Vikas Mehta (ORCID: https://orcid.org/0000-0002-7991-7422)
- X Yang (ORCID: https://orcid.org/0000-0001-8389-1889)
- Aaron Abrams
- Jae Woong Jang (ORCID: https://orcid.org/0009-0003-6898-6785)
- Marina Schnauss
Institutions
- Northwestern University (US)
Publication Details
- Journal
- Case Reports in Urology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/criu/2981515
- Citations
- 2
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 2.72